Investigational drug · Phase 2
AL58805
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "AL58805"
First trial start
2026
Sep 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AL58805", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Neoplasms
- Soft Tissue Sarcoma (STS)
- Breast Neoplasms
- Ovarian Neoplasms
- Glioblastoma
Approved drugs for the same conditions: Endometrial cancer · Brain tumors (glioma) · Sarcoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AL58805" as an intervention, largest first.
- A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNot yet recruiting
Advenchen Pharmaceuticals, LLC.Industry
NCT07811232 · 138 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2030
Drug: AL58805; AL8326 and 2 more · For: Endometrial Neoplasms; Soft Tissue Sarcoma (STS); Breast Neoplasms
Sites: Houston, Texas
- A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM CancersNot yet recruiting
Advenchen Pharmaceuticals, LLC.Industry
NCT07811297 · 138 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2030
Drug: AL58805; AL3818 and 2 more · For: Endometrial Neoplasms; Ovarian Neoplasms; Soft Tissue Sarcoma (STS) and 1 more
Sites: Houston, Texas
Advenchen Laboratories Nanjing Ltd.Industry
NCT07179081 · 40 participants (planned) · Start Dec 20, 2020 · Primary completion Jan 26, 2026
Drug: AL58805 · For: Advanced Tumors
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Endometrial Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.